NGL FINECHEM
|
NGL FINECHEM Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 33.04 | 80.68 | 91.58 | 13.14 | 32.58 |
| CEPS(Rs) | 51.45 | 97.55 | 105.30 | 26.62 | 42.78 |
| DPS(Rs) | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
| Book NAV/Share(Rs) | 360.23 | 328.94 | 250.01 | 160.18 | 149.11 |
| Tax Rate(%) | 25.09 | 25.08 | 26.90 | 30.96 | 26.99 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.57 | 21.48 | 31.05 | 13.03 | 21.08 |
| EBIT Margin(%) | 10.50 | 21.58 | 30.93 | 9.69 | 19.66 |
| Pre Tax Margin(%) | 9.84 | 20.98 | 30.08 | 7.96 | 18.00 |
| PAT Margin (%) | 7.37 | 15.72 | 21.99 | 5.50 | 13.14 |
| Cash Profit Margin (%) | 11.43 | 18.98 | 25.22 | 10.84 | 17.25 |
| Performance Ratios | |||||
| ROA(%) | 7.27 | 20.61 | 31.42 | 5.50 | 13.49 |
| ROE(%) | 9.63 | 27.90 | 44.76 | 8.72 | 21.85 |
| ROCE(%) | 11.96 | 33.91 | 53.53 | 11.93 | 25.25 |
| Asset Turnover(x) | 0.99 | 1.31 | 1.43 | 1.00 | 1.03 |
| Sales/Fixed Asset(x) | 2.07 | 2.82 | 2.75 | 1.83 | 2.07 |
| Working Capital/Sales(x) | 2.66 | 2.94 | 3.12 | 4.01 | 3.72 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.48 | 0.36 | 0.36 | 0.55 | 0.48 |
| Receivable days | 85.22 | 58.36 | 45.10 | 71.37 | 78.93 |
| Inventory Days | 54.47 | 53.95 | 46.51 | 55.95 | 44.35 |
| Payable days | 71.92 | 72.38 | 78.66 | 98.81 | 89.99 |
| Valuation Parameters | |||||
| PER(x) | 36.22 | 24.27 | 16.74 | 19.28 | 14.42 |
| PCE(x) | 23.26 | 20.07 | 14.56 | 9.52 | 10.98 |
| Price/Book(x) | 3.32 | 5.95 | 6.13 | 1.58 | 3.15 |
| Yield(%) | 0.15 | 0.09 | 0.11 | 0.69 | 0.37 |
| EV/Net Sales(x) | 2.73 | 3.90 | 3.72 | 1.20 | 2.05 |
| EV/Core EBITDA(x) | 18.74 | 15.70 | 10.88 | 7.96 | 8.63 |
| EV/EBIT(x) | 25.99 | 18.08 | 12.02 | 12.35 | 10.43 |
| EV/CE(x) | 2.64 | 4.47 | 4.62 | 1.18 | 2.11 |
| M Cap / Sales | 2.66 | 3.81 | 3.67 | 1.03 | 1.89 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -12.42 | 23.08 | 70.07 | -0.97 | - |
| Core EBITDA Growth(%) | -48.67 | -10.49 | 286.35 | -37.36 | - |
| EBIT Growth(%) | -57.38 | -14.14 | 442.89 | -51.19 | - |
| PAT Growth(%) | -58.92 | -12.03 | 580.47 | -58.59 | - |
| EPS Growth(%) | -59.05 | -11.91 | 597.04 | -59.67 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.15 | 0.15 | 0.11 | 0.29 | 0.29 |
| Current Ratio(x) | 2.79 | 2.64 | 2.98 | 1.88 | 1.91 |
| Quick Ratio(x) | 2.33 | 1.79 | 2.08 | 1.23 | 1.50 |
| Interest Cover(x) | 15.92 | 35.81 | 36.21 | 5.60 | 11.82 |
| Total Debt/Mcap(x) | 0.04 | 0.02 | 0.02 | 0.18 | 0.09 |
Compare Financial Ratios of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,576.4 Cr | 4.4% | -1.1% | 73.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,015.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,809.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,408.7 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹98,684.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹94,213.7 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 4.4% |
-1.1% |
73.9% |
| SENSEX | -2.9% |
-0.4% |
20% |
You may also like the below Video Courses
